These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 18031178)
41. Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. Sel S; Wegmann M; Dicke T; Sel S; Henke W; Yildirim AO; Renz H; Garn H J Allergy Clin Immunol; 2008 Apr; 121(4):910-916.e5. PubMed ID: 18325571 [TBL] [Abstract][Full Text] [Related]
42. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478 [TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525 [TBL] [Abstract][Full Text] [Related]
45. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Hung G; Xiao X; Peralta R; Bhattacharjee G; Murray S; Norris D; Guo S; Monia BP Nucleic Acid Ther; 2013 Dec; 23(6):369-78. PubMed ID: 24161045 [TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. Zhang R; Iyer RP; Yu D; Tan W; Zhang X; Lu Z; Zhao H; Agrawal S J Pharmacol Exp Ther; 1996 Aug; 278(2):971-9. PubMed ID: 8768755 [TBL] [Abstract][Full Text] [Related]
47. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. Aukunuru JV; Ayalasomayajula SP; Kompella UB J Pharm Pharmacol; 2003 Sep; 55(9):1199-206. PubMed ID: 14604462 [TBL] [Abstract][Full Text] [Related]
48. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070 [TBL] [Abstract][Full Text] [Related]
49. Photodynamic antisense regulation of mRNA having a point mutation with psoralen-conjugated oligonucleotide. Higuchi M; Yamayoshi A; Kobori A; Murakami A Nucleic Acids Symp Ser (Oxf); 2008; (52):515-6. PubMed ID: 18776480 [TBL] [Abstract][Full Text] [Related]
50. Liver as a target for oligonucleotide therapeutics. Sehgal A; Vaishnaw A; Fitzgerald K J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039 [TBL] [Abstract][Full Text] [Related]
51. Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. Karras JG; Crosby JR; Guha M; Tung D; Miller DA; Gaarde WA; Geary RS; Monia BP; Gregory SA Am J Respir Cell Mol Biol; 2007 Mar; 36(3):276-85. PubMed ID: 16990616 [TBL] [Abstract][Full Text] [Related]
52. Variations in mRNA content have no effect on the potency of antisense oligonucleotides. Miraglia L; Watt AT; Graham MJ; Crooke ST Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):453-61. PubMed ID: 11198929 [TBL] [Abstract][Full Text] [Related]
53. [The inhibitory effects of hepatocyte targeting pH-sensitive liposome mediated phosphorothioate antisense oligonucleotide on gene expression controlled by HCV 5'NCR]. Wang XH; Wang SQ; Wen SY; Guan W; Mao BZ Sheng Wu Gong Cheng Xue Bao; 2001 Nov; 17(6):626-30. PubMed ID: 11910753 [TBL] [Abstract][Full Text] [Related]
54. Omalizumab for severe asthma: efficacy beyond the atopic patient? Domingo C Drugs; 2014 Apr; 74(5):521-33. PubMed ID: 24691707 [TBL] [Abstract][Full Text] [Related]
55. RASONs: a novel antisense oligonucleotide therapeutic approach for asthma. Sandrasagra A; Tang L; Leonard SA; Teng K; Li Y; Mannion JC; Nyce JW Expert Opin Biol Ther; 2001 Nov; 1(6):979-83. PubMed ID: 11728229 [TBL] [Abstract][Full Text] [Related]
56. Respirable antisense oligonucleotides: a new drug class for respiratory disease. Tanaka M; Nyce JW Respir Res; 2001; 2(1):5-9. PubMed ID: 11686859 [TBL] [Abstract][Full Text] [Related]
57. Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma. Ball HA; Sandrasagra A; Tang L; Van Scott M; Wild J; Nyce JW Am J Pharmacogenomics; 2003; 3(2):97-106. PubMed ID: 12749727 [TBL] [Abstract][Full Text] [Related]
58. Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Ali S; Leonard SA; Kukoly CA; Metzger WJ; Wooles WR; McGinty JF; Tanaka M; Sandrasagra A; Nyce JW Am J Respir Crit Care Med; 2001 Mar; 163(4):989-93. PubMed ID: 11282778 [TBL] [Abstract][Full Text] [Related]